Urgent.News

What's breaking now, across thousands of outlets.

Health & Medicine

Pope Leo in Rome hospital for lung surgery

Leo has been unusually candid for a pontiff about his health issues, disclosing the surgery to thousands of people in St. Peter's Square.

Pope Leo XIV, aged 71, is set to undergo surgery on Tuesday at Rome's renowned Gemelli hospital to remove a nodule from his lung and determine if it is cancerous, the Vatican has confirmed. The pontiff disclosed the health issue during a prayer service on Sunday, marking a significant increase in transparency regarding his well-being compared to previous popes, who often provided confusing or vague statements about their health.

The surgery, which will require general anesthesia and a weeklong hospital stay, is expected to leave Leo in good condition due to the early detection of the lump. His scheduled engagements through October 20 have been cancelled, but he remains set to embark on a planned trip to South America in November.

Written by urgent.news from DW English (Top Stories)'s reporting — not their text. Machine-written — may contain errors; check the original before relying on it.

This story

This is one outlet's version. Read the fullest account.

Read the original at dw.com →

More in Health & Medicine

Nigeria: AMR - Livestock Uses More Antibiotics Than Human Health Sector - Pate

[Premium Times] Mr Pate said antimicrobial resistance could move between humans, animals and the environment, emphasising the need for collaboration across sectors.

  • Livestock sector uses more antibiotics than human health sector in Nigeria.
  • Coordinating Minister Muhammad Pate stresses responsible antibiotic use.
  • Collaboration across sectors needed to combat antimicrobial resistance.

T MAXIMUM secures US FDA clearance for Phase 2 CAR T trial

Biotechnology firm T MAXIMUM received regulatory clearance from the US Food and Drug Administration to initiate a Phase 2 trial of MT027 for secondary brain metastases

  • FDA clears T-MAXIMUM to start Phase 2 CAR T trial for MT027.
  • MT027 targets B7-H3 for recurrent glioblastoma and universal CAR-T therapy.
  • T-MAXIMUM holds Orphan Drug and Fast Track Designations for MT027.

More from Tuesday 13 October →